Proactive Investors - Run By Investors For Investors

Verona Pharma splutters as lead COPD drug disappoints in Phase II study

Ensifentrine was shown to be more effective than a placebo, although it didn’t improve patients’ breathing by as much as hoped
COPD covers a number of conditions that cause difficulty breathing

Verona Pharma PLC (LON:VRP) saw more than a fifth wiped from its value after its lead drug, a potential treatment for chronic obstructive pulmonary disease (COPD), failed to meet the primary endpoint of a mid-stage clinical trial.

The three-day Phase II study saw COPD patients given either 1.5mg or 6.0mg of ensifentrine in combination with Stiolto Respimat – a commonly used maintenance treatment for COPD patients.

Boss still optimistic

Results from the trial showed that ensifentrine did not improve breathing by a “statistically significant” amount, although it was better than a placebo

“While we are disappointed that this exploratory Phase 2 study did not achieve statistical significance for its primary endpoint, these data give us clarity on the design, including dose and background therapy, for future long-term studies,” said chief executive Jan-Anders Karlsson.

“Having demonstrated in previous studies the potential of ensifentrine to deliver benefits to patients on no or single bronchodilator therapy, we believe that this short study continues to support our view that ensifentrine may also be of benefit to more severe COPD patients on dual and triple therapy, for whom there are few other treatment options.”

The market didn’t share the same sense of optimism, with the stock slipping 21% to 82.2p on Monday morning.

View full VRP profile View Profile

Verona Pharma Timeline

June 20 2016
November 26 2010

Related Articles

Oncimmune is a specialist in the field of immunodiagnostics
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
A man's knee pain is highlighted with a red area that points to inflammation
January 22 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use